KEYTRUDA, in combination with trastuzumab, fluoropyrimidine- and platinum containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support ...

Real-world biomarker testing patterns, first line treatment and drivers of treatment choice in patients with advanced/metastatic gastric/gastroesophageal junction adenocarcinoma in the United States ...

Herceptin with chemotherapy improved OS and PFS in HER2-positive gastric cancers, but benefits decreased after chemotherapy regimen changes. Major pathological response rates were higher with ...

A groundbreaking study shows trastuzumab pamirtecan significantly improves progression-free survival in HER2-positive breast ...

Fourth Adjuvant Study Demonstrating Reduction in Risk of Disease Recurrence and Improved Survival in Early-Stage HER2-Positive Breast Cancer First Metastatic Study in Hormone Receptor-Positive and ...

Sept. 1, 2005 — The U.S. Food and Drug Administration (FDA) and Genentech, Inc., have warned healthcare professionals via letter of study data linking trastuzumab (Herceptin) therapy to a ...

ZURICH, April 23 (Reuters) - Roche subsidiary Genentech filed cancer drug Herceptin for U.S. regulatory approval for a use in treating patients with advanced stomach cancer, potentially extending its ...

LONDON (Reuters) - Roche's cancer drug Herceptin combined with chemotherapy works better than chemotherapy alone in patients with a certain type of advanced or inflammatory breast cancer, doctors said ...